Logo image
Circulating glycerate predicts resilience to fructose-induced hepatic steatosis
Journal article   Peer reviewed

Circulating glycerate predicts resilience to fructose-induced hepatic steatosis

Cuauhtemoc B Ramirez, In Sook Ahn, Varvara I Rubtsova, Ingrid Cely, Johnny Le, Joohwan Kim, Sunhee Jung, Miranda E Kelly, Yeojin Kim, Hosung Bae, …
Cell metabolism, Vol.37(5), pp.1223-1234.e5
05/06/2025
DOI: 10.1016/j.cmet.2025.03.017
PMID: 40267913
url
https://doi.org/10.1016/j.cmet.2025.03.017View
Published (Version of record) Open Access

Abstract

Excessive intake of dietary fructose increases the risk of metabolic-dysfunction-associated steatotic liver disease (MASLD), cirrhosis, and cancers. However, what host factors determine disease vulnerability is incompletely understood. Here, we leverage genetically divergent mouse strains, mass spectrometry-based metabolomics, and in vivo isotope tracing, identifying circulating glycerate as a biomarker that predicts resilience to fructose-induced hepatic steatosis in both sexes. We found that the surge of circulating glycerate after an oral fructose provision reflects strong small-intestinal fructose catabolism. Such fructose clearance by the small intestine is linked to a weaker induction of hepatic de novo lipogenesis and steatosis upon chronic fructose exposure across strains. These data indicate the potential utility of an oral fructose tolerance test and circulating glycerate measurements to predict an individual's susceptibility to fructose-elicited steatotic liver and provide personalized dietary recommendations.
Animals Biomarkers - blood Fatty Liver - blood Fatty Liver - chemically induced Fatty Liver - metabolism Female Fructose - adverse effects Fructose - metabolism Lipogenesis Liver - metabolism Liver - pathology Male Mice Mice, Inbred C57BL Non-alcoholic Fatty Liver Disease

Details

Metrics

1 Record Views
Logo image